Ella Daly, Jaskaran Singh, Maggie Fedgchin et al.
Background: Intravenous ketamine and esketamine (ESK) produce rapid antidepressant action in treatment-resistant depression (TRD) patients, however dose response is not known. Study assessed efficacy, dose response and safety of intranasal ESK and ability to sustain response with gradual tapering of treatment frequency. Methods: In the Panel A (conducted in USA and Belgium) of this...
Jun Jing, Meng-Ying Zhang, Wei-hong Yin et al.
preprint
Abstract Objective To observe the effects of esketamine on postoperative depression and pain indicators in individuals undergoing total laparoscopic hysterectomy. Methods 135 patients undegoing total laparoscopic hysterectomy were recruited and randomly allocated to three groups. Finally, a total of 127 patients were selected into the statistical analysis, with the final grouping information as...
Muyan Zuo, Yaozu Li, John P Williams et al.
preprint
Purpose: Depression combined with insomnia is a complex bidirectional relationship that is more difficult to treat versus a single disorder, and there is a lack of effective treatments available. In this study, we carried out a novel way to simultaneously intervene in depression combined with insomnia and examined functional magnetic resonance imaging (fMRI) to help further elucidate the...
Shurong Li, Zhifang Zhuo, Renwei Li et al.
preprint
Abstract Background Postpartum depression (PPD) after cesarean delivery is a common complication. Esketamine's effects on PPD in women undergoing cesarean section remain contradictory, despite ketamine's prophylactic effects. This study evaluated the effect of esketamine as an adjunct to patient-controlled intravenous analgesia (PCIA) to prevent PPD in women undergoing caesarean section....
Hannah Tramontano, Jeffrey Fetter, Mohamed Wagdy ElSayed
preprint
Background: Borderline Personality Disorder (BPD) affects 1.35% of the population and is frequently comorbid with Major Depressive Disorder (MDD), which is frequently treatment-resistant (TRD). Patients with comorbid illness have worse treatment outcomes and functional impairment. Esketamine could ameliorate symptoms of both illnesses. Methods: We conducted a retrospective chart review of...
Research Square
Alice Le Berre
preprint
Abstract Background: Treatment-resistant depression (TRD) involves impaired hippocampal plasticity. Preclinical work showed synaptic potentiation and dendritic spine growth in the dentate gyrus (DG) after esketamine (ESK), but human evidence is lacking. We aimed to detect early DG changes after ESK using advanced diffusion MRI, and to test whether baseline MRI metrics predict clinical response....